{"nctId":"NCT00902330","briefTitle":"Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer","startDateStruct":{"date":"2009-04"},"conditions":["Anxiety Disorder","Breast Cancer","Depression","Fatigue","Pain","Sleep Disorders"],"count":161,"armGroups":[{"label":"Arm I (cranial microcurrent electrical stimulation [CES])","type":"EXPERIMENTAL","interventionNames":["Procedure: energy-based therapy"]},{"label":"Arm II (sham CES)","type":"SHAM_COMPARATOR","interventionNames":["Procedure: sham intervention"]}],"interventions":[{"name":"energy-based therapy","otherNames":[]},{"name":"sham intervention","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of stage I-IIIA breast cancer\n* Scheduled to receive adjuvant chemotherapy\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Pre, peri, or post-menopausal\n* ECOG performance status 0-1\n* No dementia\n* No active psychosis\n* No history of seizure disorder\n* No implanted electrical device\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior chemotherapy\n* No initiation of a medication regimen for depression or other psychiatric condition within the past 30 days","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage Breast Cancer","description":"Using Hospital Anxiety and Depression Scale (HADS) a 14 item scale, 7 relate to anxiety, 7 to depression; each item is scored from 0-3, a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. Has 9 questions with 0 (does not interfere) to 10 (completely interferes), the total mean score is the mean of the 9 questions; severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.040","spread":"0.419"},{"groupId":"OG001","value":"4.529","spread":"0.431"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.520","spread":"0.398"},{"groupId":"OG001","value":"4.565","spread":"0.407"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.349","spread":"0.294"},{"groupId":"OG001","value":"3.191","spread":"0.301"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.174","spread":"0.197"},{"groupId":"OG001","value":"1.272","spread":"0.202"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.235","spread":"2.376"},{"groupId":"OG001","value":"40.474","spread":"2.443"}]}]}]},{"type":"SECONDARY","title":"To Examine Whether the Symptoms of Depression, Anxiety, Fatigue, Sleep Disturbances and Pain Form a Cluster.","description":"Examine correlations between the symptoms at baseline to determine a general pattern of association. Factor analysis (a statistical method used to describe variability among observed, correlated variables in terms of a potentially lower number of unobserved variables called factors) was performed to examine how these 5 symptoms cluster. A principal component factor analysis was performed on the correlation matrix for the symptom scores of anxiety, depression, pain, fatigue and sleep disturbance at up to two weeks after completion of study treatment, up to 8 months). For each analysis two factors were retained that explained 74% of the variability for the baseline symptom scores, 79% of the variability of the symptom scores at the midpoint and 78% of the variability in symptom scores at study completion. A varimax rotation was utilized and the factor loadings from the varimax rotation were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Means and Standard Deviations of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).","description":"Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.64","spread":"1.67"},{"groupId":"OG001","value":"28.92","spread":"1.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.88","spread":"69.85"},{"groupId":"OG001","value":"32.60","spread":"259.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"2.65"},{"groupId":"OG001","value":"0.09","spread":"3.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"3.49"},{"groupId":"OG001","value":"-0.19","spread":"3.49"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).","description":"Simple correlations will be computed at Baseline for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.031","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.453","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.570","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.320","spread":null}]}]}]},{"type":"SECONDARY","title":"Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Baseline","description":"Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.09","spread":"4.09"},{"groupId":"OG001","value":"7.59","spread":"4.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":"2.48"},{"groupId":"OG001","value":"3.06","spread":"2.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":"2.71"},{"groupId":"OG001","value":"2.63","spread":"2.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":"2.05"},{"groupId":"OG001","value":"1.45","spread":"1.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.70","spread":"24.83"},{"groupId":"OG001","value":"40.30","spread":"23.87"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Symptom Scores - Correlations at Baseline Chemotherapy","description":"Simple correlations will be computed at Baseline Chemotherapy for symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.610","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.303","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.298","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.474","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.343","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.315","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.488","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.482","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.492","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.388","spread":null}]}]}]},{"type":"SECONDARY","title":"Relationships Among Quality of Life Scores - Means at Baseline","description":"Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not at all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.44","spread":"17.65"},{"groupId":"OG001","value":"111.83","spread":"17.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.42","spread":"5.05"},{"groupId":"OG001","value":"26.05","spread":"6.04"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Quality of Life Scores - Correlations at Baseline","description":"Simple correlations will be computed at Baseline for quality of life scores.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.744","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).","description":"Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.62","spread":"1.69"},{"groupId":"OG001","value":"29.09","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.52","spread":"52.59"},{"groupId":"OG001","value":"24.68","spread":"171.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"2.91"},{"groupId":"OG001","value":"0.55","spread":"2.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.89","spread":"3.52"},{"groupId":"OG001","value":"-0.15","spread":"3.68"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at Midpoint Chemotherapy","description":"Simple correlations will be computed at Midpoint Chemotherapy for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.060","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.337","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.390","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.593","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.298","spread":null}]}]}]},{"type":"SECONDARY","title":"Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at Midpoint Chemotherapy","description":"Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.40","spread":"3.19"},{"groupId":"OG001","value":"4.98","spread":"3.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.24","spread":"3.22"},{"groupId":"OG001","value":"4.02","spread":"3.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.15","spread":"2.21"},{"groupId":"OG001","value":"3.14","spread":"2.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"1.44"},{"groupId":"OG001","value":"1.09","spread":"1.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.70","spread":"18.28"},{"groupId":"OG001","value":"42.44","spread":"21.73"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Symptom Scores - Correlations at Midpoint Chemotherapy","description":"Simple correlations will be computed at Midpoint Chemotherapy for symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.723","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.512","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.305","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.604","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.632","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.412","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.624","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.507","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.719","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.429","spread":null}]}]}]},{"type":"SECONDARY","title":"Relationships Among Quality of Life Scores - Means at Midpoint Chemotherapy","description":"Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not at all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111.57","spread":"18.35"},{"groupId":"OG001","value":"108.45","spread":"22.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.96","spread":"5.47"},{"groupId":"OG001","value":"25.96","spread":"5.39"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Quality of Life Scores - Correlations at Midpoint Chemotherapy","description":"Simple correlations will be computed at Midpoint Chemotherapy for quality of life scores.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.743","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean and Standard Deviation of Biomarkers Log(CRP pg/ml), Log(IL-1b pg/ml), Log(IL-6 pg/ml) and Log(TNF-a pg/ml).","description":"Simple correlations will be computed after completion of study treatment for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.64","spread":"1.26"},{"groupId":"OG001","value":"29.00","spread":"1.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.50","spread":"83.81"},{"groupId":"OG001","value":"1.35","spread":"5.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"2.29"},{"groupId":"OG001","value":"0.73","spread":"2.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"3.64"},{"groupId":"OG001","value":"-0.33","spread":"3.22"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Biomarkers Log (CRP), Log (IL-1B), Log (IL6), and Log (TNF-a) - Correlations at End of Treatment","description":"Simple correlations will be computed at Chemotherapy End of Treatment for the log transformed biomarker values; IL1-β, IL-6, TNF-α, CRP. These are the biomarkers of inflammation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.057","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.343","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.383","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.464","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.134","spread":null}]}]}]},{"type":"SECONDARY","title":"Relationships Among Anxiety, Depression, Fatigue, Pain and Sleep Scores - Means at End of Chemotherapy","description":"Measured using Hospital Anxiety and Depression Scale (HADS) a fourteen item scale, 7 relate to anxiety and 7 to depression; each item is scored from 0-3, this means a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity of pain and interference of pain in the patient's life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. it has 9 questions with 0 (does not interfere) to 10 (completely interferes); severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire scoring system.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.07","spread":"3.51"},{"groupId":"OG001","value":"4.51","spread":"4.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.47","spread":"3.36"},{"groupId":"OG001","value":"4.63","spread":"3.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.34","spread":"2.47"},{"groupId":"OG001","value":"3.32","spread":"2.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"1.65"},{"groupId":"OG001","value":"1.32","spread":"1.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.50","spread":"20.19"},{"groupId":"OG001","value":"40.91","spread":"21.21"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Symptom Scores - Correlations at End of Chemotherapy","description":"Simple correlations will be computed at end of Chemotherapy for symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.678","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.467","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.409","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.515","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.564","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.368","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.637","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.488","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.643","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.484","spread":null}]}]}]},{"type":"SECONDARY","title":"Effects of Treatment on Quality of Life - Means at End of Treatment","description":"Measured using the Functional Assessment of Cancer Therapy for Patients with Breast Cancer (FACT-B). A 44-item self-report instrument designed to measure multidimensional quality of life in patient with breast cancer. 0=not at all to 4=very much. Utilized standard questionnaire scoring system. The items are summed to produce a total score 0=not al all to 176=very much. The FACT-B BCA has 10 questions that range from 0 (not at all) to 4 (very much); thus the FACT-B BCA ranges from 0 to 40. Both the FACT-B and FACT-BCA are scored so that high scores indicate higher levels of quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108.11","spread":"2.52"},{"groupId":"OG001","value":"105.96","spread":"2.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.51","spread":"0.75"},{"groupId":"OG001","value":"24.66","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Relationships Among Quality of Life Scores - Correlations at End of Chemotherapy","description":"Simple correlations will be computed at End of Chemotherapy for quality of life scores.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.772","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":77},"commonTop":[]}}}